A novel substituted N-acetyl-L-cysteine (NAC) derivative and methods of using this compound for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

Substituted phenylcarbamoyl alkylamino arenes; substituted phenylthiocarbamyl alkylamino arenes; substituted phenylcarbamoyl alkylamino heteroarenes; substituted phenylthiocarbamyl alkylamino heteroarenes; N-substituted aryl, N'-substituted aryl urea compounds; N-substituted aryl, N'-substituted heteroaryl urea compounds; N-substituted aryl, N'-substituted aryl thiourea compounds and N-substituted aryl, N'-substituted heteroaryl thiourea compounds are provided and may find use as androgen receptor modulators. The compounds may find particular use in treating prostate cancer, including castration-resistant prostate cancer and/or hormone-sensitive prostate cancer.

The present invention relates to processes for preparing 3-methylsulfonylpropionitrile. The processes provide a good yield and a good purity of the final product and provide a controllable reaction. The present invention also relates to a crystalline form of 3-methylsulfonylpropionitrile having X-ray diffraction peaks at 13.9±0.1, 19.2±0.1, 20.0±0.1, 22.5±0.1, 23.2±0.1, 25.7±0.1, 28.1±0.1, 29.9±0.1, and 30.6±0.1 degrees 2θ, and wherein the most intense peak is the peak at 13.9±0.1 degrees 2θ.

The present application relates to novel 3-phenylpropionic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.

The present invention is directed to L-proline and citric acid co-crystals of (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, pharmaceutical compositions containing said co-crystals and their use in the treatment glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X.

The present invention relates to novel 1,2,3-triazolyl purine derivatives. The invention also relates to using the derivatives to treat cancer and various viral infections. An example of a 1,2,3-triazolyl purine derivative of the invention is

Provided are a three-dimensional (3D) ultrasound system and a method for operating the 3D ultrasound system, which are capable of intuitively displaying the abnormality of an object by determining a grade by comparing measurement data obtained by measuring ultrasound data relating to the object and displaying the measurement data in a different way based on the determined grade.

Method for preparing diamino-dianhydro-dideoxyhexitols, particularly 2,5-diamino-1,4:3,6-dianhydro-2,5-dideoxy-D-hexitol. The invention related to a method for preparing diamino-dianhydro-dideoxyhexitols, particularly preferably 2,5-diamino-1,4:3,6-dianhydro-2,5-dideoxy-D-hexitol.

A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.

The present invention is directed to 5-sec-butyl-2-(2,4-dimethyl-cyclohex-3-enyl)-5-methyl-[1,3]dioxane and a novel process for making the same.

The present invention relates to a novel method for preparing methylene-1,3-dioxolanes of the general formula (I) in which R1 and R2 have the meanings stated in the description. Methylene-1,3-dioxolanes are important intermediates for preparing pyrazoles and anthranilic acid amides, which may be used as insecticides.

The invention relates to a process for preparing 1-aryl-pyrazol-3-one intermediates, tautomers, and salts thereof, to novel intermediates, and to the use of the intermediates in the preparation of sigma receptor inhibitors.

The present invention relates to a process for the preparation of 17α-(3-hydroxypropyl)-17β-hydroxysteroids of the formula I starting from 17-ketosteroids of the formula III via the intermediates of the formula V wherein the radicals R3, R5, R6, R7, R10, R13, R15, R16, R40, R41 and R42 have the meaning indicated in the description.

Disclosed are methods of purifying (20R) and (20S) analogs of 2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 to obtain the (20R) and (20S) analogs in crystalline form. The method includes the steps of preparing a solvent of either diethyl ether or a mixture of 2-propanol and hexane, dissolving a product containing the (20R) and (20S) analog to be purified in the solvent, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of crystals, and recovering the crystals.

The present invention provides novel 16,23-diene 25-oxime ether analogs of 1,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the novel compound of the invention are useful for treating diseases which benefit from a modulation of the levels of 1,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-3 cycloalkenyl triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV: wherein X can be a C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6-9 oxaspirocycloalkyl, or C6-9 oxaspirocycloalkenyl ring. These compounds are useful for the treatment of HIV and AIDS.

The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.

Disclosed are methods of purifying the compound (20R)-2-methylene-19-nor-24-difluoro-1α,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the compound in a solvent comprising hexane and 2-propanol, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of crystals, and recovering the crystals.

The present invention provides for a practical, universal and efficient method to ligate two large macromolecules (e.g., proteins) using the alkyne-azide 1,3-dipolar cycloaddition reaction to produce a conjugated macromolecule, such as a multivalent scFv. The present invention also provides for conjugate macromolecules comprising a plurality of macromolecule components cross-linked through at least one linking group comprising at least one 1,2,3-triazole moiety, wherein at least 50 percent of the macromolecule components in the conjugate macromolecule has only one site available for cross-linking.

This invention discloses 3-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D3 and (20R)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D3 as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to monocytes thus evidencing use as anti-cancer agents especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. These compounds also exhibit relatively high calcemic activity evidencing use in the treatment of bone diseases.

To provide a novel vitamin D3 derivative useful as a therapeutic agent for osteoporosis. Provided is a vitamin D3 derivative represented by the following formula (1) or a medicinally acceptable solvate thereof: wherein R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkylcarbonyloxyalkyl group with each alkyl having 1 to 6 carbon atoms, or an arylcarbonyloxyalkyl group with the aryl having 6 to 10 carbon atoms and the alkyl having 1 to 6 carbon atoms; R2 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or, together with the other R2 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; R3 represents an alkyl group having 1 to 6 carbon atoms or, together with the other R3 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; X represents an oxygen atom or a methylene group; and n represents an integer of 1 or 2.

The invention discloses a method for producing 30-halogenated betulinic acid. Betulin is used as a raw material and selectively oxidized and halogenated to generate 30-betulinic acid, and the selected oxidation and halogenation agent has high selectivity and does not affect C-3 hydroxyl or carbon-carbon double bonds. Oxidation and halogenation are completed in one step, so the process route is short, the treatment method is simple, and the product is purified easily.

Disclosed are methods of purifying the compound (20R)-19-nor-24-difluoro-1α,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the compound in a solvent comprising hexane and 2-propanol, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of crystals, and recovering the crystals.

N-Substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines are effective at controlling insects.

The present invention discloses a method of inhibiting an ethylene response in a plant, comprising step of applying to at least one portion of the plant an effective ethylene response-inhibiting amount of a H1-cyclopropene-1-propanoic acid salt (CPAS). A method of prolonging the life of a cut flower, comprising applying to the cut flower an effective life-prolonging amount of CPAS and a method for the production a CPAS, comprising steps of (i) preparing 4-bromo-4-pentenoic acid or derivatives thereof; (ii) producing 1-cyclopropene-1-propanoic acid; and (iii), converting this acid into its water soluble salt, especially its sodium salt are presented. Additionally, a new family of water soluble CPAS inhibitors for ethylene response in a plant is disclosed.

Benzoyl derivatives of the formula I where the variables have the following meanings: R1, R2 are hydrogen, nitro, halogen, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl or C1-C6-haloalkylsulfonyl;R3 is hydrogen, halogen or alkyl;R4, R5 are hydrogen, halogen, cyano, nitro, alkyl, alkoxy, alkylthio, dialkylamino, phenyl or carbonyl, it being possible for the 6 last-mentioned radicals to be substituted;X is O, S, NR9, CO or CR10R11;Y is O, S, NR12, CO or CR13R14;R15 is pyrazole which is unsubstituted or substituted, linked in the 4-position and has attached to it in the 5-position a hydroxyl or sulfonyloxy radical; and the agriculturally useful salts thereof; processes and intermediates for the preparation of the 3-heterocyclyl-substituted benzoyl derivatives; compositions comprising them; and the use of these derivatives or compositions comprising them for controlling undesirable plants.

A method of modelling a hydrocarbon-containing reservoir which is representative of such reservoir in at least one physical characteristic such as reservoir porosity or permeability. Data, such as reservoir porosity is firstly determined. Such data is then transformed into printing instructions for a 3D printer. The 3D printer is used to print a reduced-scale model which is representative of the reservoir in respect of the at least one physical characteristic, such as reservoir porosity. A method of comparative testing of different hydrocarbon recovery techniques on a single hydrocarbon-containing reservoir is also disclosed and claimed.

In a method for simulating temperature and electrical characteristics within an circuit, a temperature of at least one volume within the circuit as a function of a resistance within the at least one volume is repeatedly calculated and the resistance as a function of the temperature is repeatedly calculated until the temperature is within a predetermined tolerance of a previous temperature result and until the resistance is within a predetermined tolerance of a previous resistance result. Once the temperature is within a predetermined tolerance of the previous temperature result and the resistance is within a predetermined tolerance of the previous resistance, then an output indicative of the temperature is generated.

The portable, wearable, proximal Alzheimer's disease treatment invention is based upon creating an RF field of particular frequencies and intensities that are applied to the patient's head. To accomplish the aforementioned disease treatment functionality, a system was invented comprising a network of antennas connected to an RF generator via a feedline connector. The invention also provides methods for using measurements to monitor and manage the effectiveness of an ongoing disease treatment regimen, and databases which contain information about measurements, variables, and their relationships to clinical outcome.

A novel soybean variety, designated XR31L13 is provided. Also provided are the seeds of soybean variety XR31L13, cells from soybean variety XR31L13, plants of soybean XR31L13, and plant parts of soybean variety XR31L13. Methods provided include producing a soybean plant by crossing soybean variety XR31L13 with another soybean plant, methods for introgressing a transgenic trait, a mutant trait, and/or a native trait into soybean variety XR31L13, methods for producing other soybean varieties or plant parts derived from soybean variety XR31L13, and methods of characterizing soybean variety XR31L13. Soybean seed, cells, plants, germplasm, breeding lines, varieties, and plant parts produced by these methods and/or derived from soybean variety XR31L13 are further provided.

The invention relates to the soybean variety designated A1036101. Provided by the invention are the seeds, plants and derivatives of the soybean variety A1036101. Also provided by the invention are tissue cultures of the soybean variety A1036101 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety A1036101 with itself or another soybean variety and plants produced by such methods.

The invention relates to the soybean variety designated A1036360. Provided by the invention are the seeds, plants and derivatives of the soybean variety A1036360. Also provided by the invention are tissue cultures of the soybean variety A1036360 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety A1036360 with itself or another soybean variety and plants produced by such methods.

The present invention provides an inbred corn line designated HID3483, methods for producing a corn plant by crossing plants of the inbred line HID3483 with plants of another corn plant. The invention further encompasses all parts of inbred corn line HID3483, including culturable cells. Additionally provided herein are methods for introducing transgenes into inbred corn line HID3483, and plants produced according to these methods.

A novel maize variety designated X08D387 and seed, plants and plant parts thereof, produced by crossing Pioneer Hi-Bred International, Inc. proprietary inbred maize varieties. Methods for producing a maize plant that comprises crossing hybrid maize variety X08D387 with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into X08D387 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. This invention relates to the maize variety X08D387, the seed, the plant produced from the seed, and variants, mutants, and minor modifications of maize variety X08D387. This invention further relates to methods for producing maize varieties derived from maize variety X08D387.

A novel maize variety designated PH1W03 and seed, plants and plant parts thereof. Methods for producing a maize plant that comprise crossing maize variety PH1W03 with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH1W03 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. Hybrid maize seed, plant or plant part produced by crossing the variety PH1W03 or a locus conversion of PH1W03 with another maize variety.

The present invention provides an inbred corn line designated KLI6131, methods for producing a corn plant by crossing plants of the inbred line KLI6131 with plants of another corn plant. The invention further encompasses all parts of inbred corn line KLI6131, including culturable cells. Additionally provided herein are methods for introducing transgenes into inbred corn line KLI6131, and plants produced according to these methods.

According to the invention, there is provided seed and plants of the corn variety designated CV052803. The invention thus relates to the plants, seeds and tissue cultures of the variety CV052803, and to methods for producing a corn plant produced by crossing a corn plant of variety CV052803 with itself or with another corn plant, such as a plant of another variety. The invention further relates to corn seeds and plants produced by crossing plants of variety CV052803 with plants of another variety, such as another inbred line. The invention further relates to the inbred and hybrid genetic complements of plants of variety CV052803.

A novel maize variety designated X130721 and seed, plants and plant parts thereof, produced by crossing Pioneer Hi-Bred International, Inc. proprietary inbred maize varieties. Methods for producing a maize plant that comprises crossing hybrid maize variety X130721 with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into X130721 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. This invention relates to the maize variety X130721, the seed, the plant produced from the seed, and variants, mutants, and minor modifications of maize variety X130721. This invention further relates to methods for producing maize varieties derived from maize variety X130721.

In an embodiment, the invention relates to the seeds, plants, and plant parts of canola variety SCV435009 and to methods for producing a canola plant produced by crossing canola variety SCV435009 with itself or with another canola variety. The invention also relates to methods for producing a canola plant containing in its genetic material one or more transgenes and to the transgenic canola plants and plant parts produced by those methods. This invention also relates to canola varieties or breeding lines and plant parts derived from canola variety SCV435009, to methods for producing other canola varieties, lines or plant parts derived from canola variety SCV435009 and to the canola plants, varieties, and their parts derived from use of those methods. The invention further relates to hybrid canola seeds, plants and plant parts produced by crossing the variety SCV435009 with another canola variety.

The invention relates to the soybean variety designated A1035446. Provided by the invention are the seeds, plants and derivatives of the soybean variety A1035446. Also provided by the invention are tissue cultures of the soybean variety A1035446 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety A1035446 with itself or another soybean variety and plants produced by such methods.

According to the invention, there is provided seed and plants of the hybrid corn variety designated CH715413. The invention thus relates to the plants, seeds and tissue cultures of the variety CH715413, and to methods for producing a corn plant produced by crossing a corn plant of variety CH715413 with itself or with another corn plant, such as a plant of another variety. The invention further relates to genetic complements of plants of variety CH715413.

A wheat variety designated W030377L1, the plants and seeds of wheat variety W030377L1, methods for producing a wheat plant produced by crossing the variety W030377L1 with another wheat plant, and hybrid wheat seeds and plants produced by crossing the variety W030377L1 with another wheat line or plant, and the creation of variants by mutagenesis or transformation of variety W030377L1. This invention also relates to methods for producing other wheat varieties or breeding lines derived from wheat variety W030377L1 and to wheat varieties or breeding lines produced by those methods.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

A description is given of N-(1,2,5-oxadiazol-3-yl)pyridinecarboxamides of the general formula (I) as herbicides. R in this formula (I) stands for radicals such as hydrogen, organic radicals, and other radicals such as halogen. W stands for a substituted pyridyl radical.

This disclosure is directed to fused tetracyclic pyrido[4,3-b>]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

The present invention is directed to a compound of Formula (I) and to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

Additional bandwidth is provisioned to layer 2/3 networks by initially provisioning optical wavelength channels to meet incremental needs for additional capacity. When bandwidth requirements grow large enough, a wavelength-sized channel is provisioned to meet the bandwidth needs, and the previously provisioned optical wavelength channels are freed up to be reused for additional growth. The optical wavelength channels may be channelized VLANs mapped to resizable optical channel data units such as ODUflex units.

The present invention pertains to systems and methods for the capture of information regarding scenes using single or multiple three-dimensional LADAR systems. Where multiple systems are included, those systems can be placed in different positions about the imaged scene such that each LADAR system provides different viewing perspectives and/or angles. In accordance with further embodiments, the single or multiple LADAR systems can include two-dimensional focal plane arrays, in addition to three-dimensional focal plane arrays, and associated light sources for obtaining three-dimensional information about a scene, including information regarding the contours of the objects within the scene. Processing of captured image information can be performed in real time, and processed scene information can include data frames that comprise three-dimensional and two-dimensional image data.

A catalyst comprising of nano nickel-silica catalyst for dewaxing of heavy petroleum feed at a temperature 200-350° C. at 8 bar and 30 bar hydrogen pressure and in the presence of hydrogen is designed for petrochemical industries. According to a specific aspect of the invention, the nano catalyst is designed and employed to convert heavy hydrocarbon feeds of high viscosity index to low pour point and good stability in a single step.

Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids were prepared chemically and/or enzymatically. Depending upon the ester, improved melanocyte cytotoxicity was achieved. Improved cytotoxicity characteristics are consistent with ester analogs being more physiologically compatible and less irritating to skin than their corresponding acids.